BJMO - volume 12, issue 8, december 2018
L. Polastro , J. Kerger MD, PhD
During this year’s ESMO Congress in Munich, which was attended by over 28,000 participants, the vast majority of presentations and communications in the gynaecological cancer domain were devoted or restricted to ovarian cancer. This included at least one major breakthrough and practice-changing study in the first-line treatment of BRCA mutated high grade serous and endometrioid ovarian cancer.
Read more
Top
